US4081431A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Blood fractionation
Assignee: Biotest Serum Institut GmbH
•
Filing: 1975-12-11
•
Granted: 1978-03-28
•
Expires: 1995-12-11
Abstract
Abstract A process for the fractionation of blood comprising passing said blood through a cation exchanger, separating the solids from the plasma, freezing the plasma, thawing the frozen plasma, and separating a first product comprising undissolved cryoprecipitate enriched in factor-VIII protein from plasma fluid. The cryoprecipitate can be concentrated by warm water dissolution and polyethylene glycol precipitation. The plasma fluid, optionally after treatment with beta -propiolactone and uv irridiation, is treated with tricalcium phosphate to adsorb factors II, VII, IX and X as a second product. These factors can be eluted with citrate solution. The residual plasma from the initial tricalcium phosphate adsorption is treated with colloidal silica to adsorb impurities and leave a third product which is a storage-stable serum protein solution.
Inventors
- 👤 Wolfgang Stephan
- 👤 Ronald Kotitschke
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-26 01:18
CPC Classifications
C; C12; C12N; C12N9/00; C12N9/14; C12N9/48; C12N9/50; C12N9/64; C12N9/6421; C12N9/6424; C12N9/6429; C07; C07K; C07K14/00; C07K14/435; C07K14/745; C07K14/755; C12Y; C12Y304/00; C12Y304/21; C12Y304/21005; A; A61; A61K; A61K38/00; Y; Y10; Y10S; Y10S530/00; Y10S530/827; Y10S530/829; Y10S530/83
Claims Analysis
Total Claims: 11
Claim 1
Independent Claim
144 words
A process for the fractionation of blood consisting essentially of sequentially taking blood from a donor, passing said blood through a cation exchanger, separating the solids from the plasma, freezing the plasma, thawing the frozen plasma and separating from the thawed plasma fluid a first product comprising undissolved cryoprecipitate enriched in factor-VIII protein; dissolving the first product, removing impurities from the solution of the first product, precipitating the factor-VIII protein from the solution; after separation of the first product treating the residual thawed plasma fluid with a solid adsorbent thereby to adsorb the factors II, VII, IX and X, and separating a second product comprising solid adsorbent and the adsorbed factors from the residual plasma; and, after separation of the second product, contacting the residual plasma with colloidal silica and separating a third product comprising a storage-stable serum protein solution from the colloidal silica.
Claim 2
Dependent Claim
144 words
A process for the fractionation of blood consisting essentially of sequentially taking blood from a donor, passing said blood through a cation exchanger, separating the solids from the plasma, freezing the plasma, thawing the frozen plasma and separating from the thawed plasma fluid a first product comprising undissolved cryoprecipitate enriched in factor-VIII protein; dissolving the first product, removing impurities from the solution of the first product, precipitating the factor-VIII protein from the solution; after separation of the first product treating the residual thawed plasma fluid with a solid adsorbent thereby to adsorb the factors II, VII, IX and X, and separating a second product comprising solid adsorbent and the adsorbed factors from the residual plasma; and, after separation of the second product, contacting the residual plasma with colloidal silica and separating a third product comprising a storage-stable serum protein solution from the colloidal silica.
Claim 3
Dependent Claim
24 words
A process according to claim 1, wherein the plasma is frozen less than about 4 days after the blood is taken from a donor.
Claim 4
Dependent Claim
14 words
A process according to claim 1, wherein freezing is effected at about -40° C.
Claim 5
Dependent Claim
16 words
A process according to claim 1, wherein thawing is effected at about 2° to 8° C.
Claim 6
Dependent Claim
13 words
A process according to claim 1 wherein the solid adsorbent is tricalcium phosphate.
Claim 7
Dependent Claim
23 words
A process according to claim 5, wherein the residual thawed plasma fluid is treated with β-propiolactone prior to contact with the tricalcium phosphate.
Claim 8
Dependent Claim
23 words
A process according to claim 5 wherein the colloidal silica has a specific surface area of about 50 to 400 m 2 /g.
Claim 9
Dependent Claim
76 words
A process according to claim 7, wherein the plasma is frozen at about -40° C less than about 48 hours after the blood is taken from a donor, thawing is effected at about 2° to 8° C, the first product is dissolved in warm water and impurities therein are removed by adsorption on Al(OH) 3 gel, and the plasma fluid separated from the first product is treated with β-propiolactone prior to contact with the tricalcium phosphate.
Claim 10
Dependent Claim
29 words
A process according to claim 8, wherein polyethylene glycol is added to the warm water solution of the first product in an amount sufficient to precipitate the factor-VIII protein.
Claim 11
Dependent Claim
9 words
Blood fractions produced by the process of claim 1.
References Cited (Backward Citations)
US3652530A
Cited
US3916026A
Cited
US3682881A
Cited
US3869436A
Cited
US3920625A
Cited
US3973002A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1981-03-27 | 1981-09-26 | 1982-03-28 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1985-03-27 | 1985-09-26 | 1986-03-28 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1989-03-27 | 1989-09-26 | 1990-03-28 | $7700.00 | Window Closed / Lapsed |